ArticleJournal of immunology research2020
Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma.
Article in Journal of immunology research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- Cell therapy in sarcoma: current landscape and future directions.Journal for immunotherapy of cancer · 2026Review
- Advancements in Osteosarcoma Therapy: Overcoming Chemotherapy Resistance and Exploring Novel Pharmacological Strategies.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Peripheral immune biomarkers associated with response to adoptive cell therapy with tumor infiltrating lymphocytes.Clinical and experimental immunology · 2025Article
- Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges.BMJ oncology · 2025Review
- Serial TIL infusions and PD-1 blockade drive long-term clonal persistence in prostate cancer.Frontiers in oncology · 2025Article
- Decoding the immune microenvironment in osteosarcoma: new insights into checkpoints, vaccines, and CAR-T cells.Frontiers in oncology · 2025Review
- Adoptive cell therapy for cancer: combination strategies and biomarkers.Frontiers in immunology · 2025Review
- Osteosarcoma: A comprehensive review of model systems and experimental therapies.Medical research archives · 2024Article
- Biomarkers for response to TIL therapy: a comprehensive review.Journal for immunotherapy of cancer · 2024Review
- Role of Immunotherapy in Sarcomas.International journal of molecular sciences · 2024Review
- Immunotherapy of osteosarcoma based on immune microenvironment modulation.Frontiers in immunology · 2024Review
- Clinical Trials of Cellular Therapies in Solid Tumors.Cancers · 2023Review
- Current Landscape of Immunotherapy for Advanced Sarcoma.Cancers · 2023Review
- Osteosarcoma: Current Concepts and Evolutions in Management Principles.Journal of clinical medicine · 2023Review
- Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.Signal transduction and targeted therapy · 2022Review
- Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?Frontiers in immunology · 2022Review
- Exploring the landscape of immunotherapy approaches in sarcomas.Frontiers in oncology · 2022Review
- Potential biomarkers: Identifying powerful tumor specific T cells in adoptive cellular therapy.Frontiers in immunology · 2022Review
- Lung Immune Prognostic Index Could Predict Metastasis in Patients With Osteosarcoma.Frontiers in surgery · 2022Article
- The perplexing role of immuno-oncology drugs in osteosarcoma.Journal of bone oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe pathological subtype of osteosarcoma is one of the most common malignant bone tumors. Notably, chemotherapy-resistant metastatic osteosarcoma has been reported to cause significant mortality and shows poor prognosis with the currently available multidisciplinary treatments. This study investigated whether combined adoptive TIL and anti-PD1 therapy improves the prognosis of patients with chemotherapy-resistant metastatic osteosarcoma.
methodsA total of 60 patients with chemotherapy-resistant metastatic osteosarcoma between June 2016 and March 2018 were enrolled. The primary endpoint was to evaluate the safety and adverse effects (AEs) of infusions of TIL and anti-PD1 therapy in the patients. Besides, secondary endpoints included assessing the objective response rate (ORR), progression-free survival time (PFS), and overall survival time (OS).
resultsWe reported that combined TIL therapy and anti-PD1 therapy is safe and all treatment-related AEs were reversible or manageable. The ORR of all the patients is 36.67%, and patients with more infusions of TIL and CD8
conclusionThis study determined that combined TIL and anti-PD1 therapy is safe and effective in metastatic osteosarcoma patients with chemotherapy resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.